MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) jointly announced today the closing of the transactions under the Asset ...
BioTime, Inc. announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human Embryonic Stem (hES) cell lines available to California-based ...
Recently, BioTime and LifeMap Sciences, along with another BioTime subsidiary, OrthoCyte Corporation, reported in the peer-reviewed journal Regenerative Medicine a means of manufacturing distinct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results